Loupe-Based Intraoperative Fluorescence Imaging
Part of paid clinical trials in Lexington, Kentucky.
- Sponsor
- Guoqiang Yu
- Study ID
- NCT04780009
- Status
- Recruiting
Conditions
- Anaplastic Astrocytoma
- Glioblastoma Multiforme
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 90 Years
- Healthy Volunteers
- Not accepted
Study Details
Glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA) are the most common primary malignant brain tumors. Survival of patients with these brain tumors is directly related to the extent of resection. Consequently, a great deal of effort has been directed at developing techniques and technologies that allow more extensive, safe resections. This study will test a loupe-based wearable device in the clinical setting and compare its accuracy with a large operative microscope to identify tumor tissues. Postoperative histopathological analysis on tumor tissues will be used as gold standards for comparison. The outcome from this study will be a low-cost, miniaturized, easy-to-operate, loupe-based fluorescence imaging device for intraoperative guidance of brain tumor resection with the same level of accuracy as the large microscope.
Key Dates
- Start date
- Nov 17, 2017
- Status verified
- Jun 2026
- Primary completion
- Aug 31, 2027
- Completion
- Aug 31, 2027
Study Design
- Enrollment
- 30 participants (estimated)
Primary Outcome Measure
Positive Predictive Value (PPV) [ Time Frame: 1 day ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Kentucky | Lexington | Kentucky | 40536 | Thomas Pittman, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Lexington, KY
Related Studies
- Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma MultiformeRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AAPHASE1/PHASE2 · Recruiting · Northwell Health · New York, New York
- Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated GliomaPHASE1/PHASE2 · Recruiting · Neonc Technologies, Inc. · Los Angeles, California
- Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOAPHASE2 · Recruiting · Northwell Health · New York, New York